Martin Dietrich, MD, PhD, presents a thorough analysis of HER2 as a pan-tumor biomarker, underscoring its universal importance in the field of oncology.

Martin Dietrich, MD, PhD, reflects on the lessons and insights gleaned from HER2 in breast cancer, examining their influence on the development of treatment approaches utilizing HER2-targeted therapies in other solid tumors.

Martin Dietrich, MD, PhD, offers a comprehensive review of the efficacy and safety of HER2 ADCs in breast cancer, underscoring their substantial impact on treatment practices in both HER2+ and HER2-low.

Martin Dietrich, MD, PhD, examines the safety and efficacy of HER2-directed ADCs in NSCLC, emphasizing significant differences in response associated with HER alterations.

Martin Dietrich, MD, PhD, discusses the role of HER2 ADCs in GI cancers, reviewing key data from DESTINY-Gastric and DESTINY-CRC trials.

Ritu Salani, MD, presents an outline of the treatment landscape for ovarian cancer and underscores encouraging data from the DESTINY-PanTumor02 study, showcasing promising results in this treatment setting.

Ritu Salani, MD, discusses impactful efficacy signals from T-DXd in the DESTINY-PanTumor02 study for endometrial cancer, marking a potential breakthrough in this treatment field.

Ritu Salani, MD, highlights impactful findings from the DESTINY-PanTumor02 study in patients with cervical cancer, highlighting the promising role of HER2-directed ADCS in this treatment space.

Ritu Salani, MD, provides expert insights regarding HER2 testing in patients with gynecological cancers, emphasizing the need for standardization in testing practices and greater clarity surrounding the incidence of HER2 positivity across gynecological cancers.

Martin Dietrich, MD, PhD, and Ritu Salani, MD, share their outlook on the future roles of HER2-directed ADCs in gynecological cancers and other solid tumors, highlighting the necessity for additional research to provide further understanding in these areas.